Krish S. Krishnan is the Chair and Chief Executive Officer of KRYSTAL BIOTECH INC, a pioneering company in the field of genetic medicine. With a robust background in biotechnology and pharmaceuticals, Krishnan has been instrumental in steering KRYSTAL BIOTECH towards groundbreaking advancements in gene therapy. Prior to his role at KRYSTAL BIOTECH, Krishnan held various leadership positions in the industry, including key roles at companies like Gilead Sciences and Medivation, where he honed his skills in strategic planning and product development. Under Krishnan's leadership, KRYSTAL BIOTECH has made significant strides in developing innovative treatments for rare diseases. One of his notable achievements includes the development of KB105, a potential first-in-class treatment for dystrophic epidermolysis bullosa, which has shown promising results in clinical trials. Krishnan's vision for the company extends beyond immediate therapeutic solutions; he is dedicated to building a sustainable pipeline of gene therapies that address unmet medical needs. His strategic foresight and commitment to scientific excellence have positioned KRYSTAL BIOTECH as a leader in the rapidly evolving field of genetic medicine. As the Chair and CEO, Krishnan plays a pivotal role in shaping the company's direction and culture. He fosters an environment of collaboration and innovation, encouraging his team to push the boundaries of what is possible in gene therapy. Krishnan's leadership is characterized by a blend of scientific rigor and business acumen, which has been crucial in navigating the complex landscape of biopharmaceutical development. His contributions to the field have not only propelled KRYSTAL BIOTECH forward but have also made a lasting impact on the broader scientific community.